SARC041 Earns Prestigious ASCO 2026 Plenary Selection

We extend our congratulations to SARC041 principal investigator Dr. Mark Dickson (Memorial Sloan Kettering Cancer Center, NY, NY, USA) and clinical collaborators for the selection of “SARC041: A Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Patients with Advanced Dedifferentiated Liposarcoma” for presentation during the highly prestigious Plenary Session of the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Dr. Dickson will present SARC041 in Hall B1 on Sunday, May 31, 2026, starting at 1:39 pm CT, followed by discussant insights from Dr. Paolo Giovanni Casali (La Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT) at 1:51 pm CT.

This is a wonderful opportunity to increase sarcoma’s (and rare cancers in general) visibility during ASCO and will surely hearten sarcoma patients, survivors, and loved ones. We also thank Eli Lilly & Co. for funding support for this important investigator-initiated, SARC-sponsored clinical trial.